Recursion's Incoming CEO Needs To Prove That AI Drug Development Can Pay Off
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around?
(Forbes, 2025-11-17T11:30:00Z)